Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
Status:
Completed
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
Cognitive and functional decline observed in atrial fibrillation (AF) patients are related to
thrombotic and/or cardioembolic events. Use of warfarin for the prevention of stroke in AF
patients, despite effective, remains beyond desired levels because of interactions with food
and fluctuations in blood levels. Because of a more stable anticoagulation state, Dabigatran
may offer better protection against thrombotic phenomenon and, consequently, mitigate the
process of cognitive and functional compromise.
Phase:
Phase 4
Details
Lead Sponsor:
University of Sao Paulo
Collaborators:
Boehringer Ingelheim Federal University of Minas Gerais